The indication for Anlotinib combined with Penpulimab for the first-line treatment of advanced hepatocellular carcinoma was approved for marketing. This is the tenth approved indication for Anlotinib and the fifth approved indication for Penpulimab.

The "2025 Technology + New Quality Productive Forces Summit Forum" was held in Hong Kong. Ms. Cheng Cheung Ling, President of the Hong Kong China Friendship Association and President of CP Pharmaceutical Group, attended and delivered a speech. Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, delivered a speech titled "Biopharmaceuticals: The Health Revolution and Industrial Wave under New Quality Productive Forces".

Culmerciclib Capsules (Saitanxin®), the world's first CDK2/4/6 inhibitor, was approved for marketing in combination with Fulvestrant for patients with HR+/HER2- locally advanced or metastatic breast cancer who have previously received endocrine therapy. It provides a new treatment option for issues such as resistance to CDK4/6 inhibitors and reducing myelosuppression.

The "National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2025)" was announced. Garsorasib, Recombinant Human Coagulation Factor VIIa N01, and Penpulimab were included in the list for the first time, while Anlotinib, Efbemalenograstim alfa, and others were successfully renewed for reimbursement with upgraded benefits.

Lidocaine Cataplasms (Debaining®), developed by Beijing Tide Pharmaceutical, was approved for a new indication for the treatment of diabetic peripheral neuropathic pain (DPNP). It is the world's first and currently only topical analgesic cataplasm approved for this indication.

Ms. Cheng Cheung Ling, President of CP Pharmaceutical Group, and Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, announced that Sino Biopharm donated HKD 10 million in cash and medicine for the emergency resettlement and basic living support during the transition period for compatriots affected by the fire in Tai Po, Hong Kong.

Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharm, attended the 17th China Healthcare Summit of Entrepreneurs, Scientists and Investors 2025 (Qisi Conference) and delivered a speech titled "Sino Biopharm: A New Decade, A New Starting Point".

Following the release of the " Carbon Neutrality Target Roadmap of Sino Biopharmaceutical Limited", Sino Biopharm further launched the "Phase I Implementation Plan for Carbon Neutrality Action" to promote the solid implementation of its low-carbon transition and the timely achievement of its carbon neutrality goals.

LM-350 (a CDH17 Antibody-Drug Conjugate), independently developed by LaNova Medicines, received IND approval from the China NMPA, enabling simultaneous development in China, the US, and Australia.

Chia Tai Fenghai and Chia Tai Tianqing Nanjing Shunxin Pharmaceutical Co., Ltd. were selected as "Jiangsu Provincial Green Factories" in 2024 and 2025, respectively. To date, Sino Biopharm has successfully established 2 national-level and 4 provincial-level green factories.

Deutetrabenazine Tablets, developed by Nanjing Chia Tai Tianqing, was approved as a first-to-file generic for the treatment of Huntington's chorea, marking significant progress for domestic companies in the highly challenging R&D field of deuterated drugs.

The inaugural academic committee establishment meeting for the Jiangsu Key Laboratory of Antiviral Drug Research was held in Nanjing. The laboratory is led by Chia Tai Tianqing and jointly established with the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences.

Chia Tai Qingjiang was successfully selected as a 2025 national-level specialized and sophisticated "Little Giant" enterprise; Beijing Tide Pharmaceutical was selected for the ninth batch of "Manufacturing Single Champion Enterprises".

The 2025 International Biomedical Industry Innovation Conference Beijing Forum held its plenary session, and 12 medical companies, including Sino Biopharm, moved into the International Medical Innovation Park (BioPark).

The 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan. Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, attended a meeting organized by Lin Wu, Secretary of the Shandong Provincial Party Committee. Over 30 of Sino Biopharm's studies were selected, and Efbemalenograstim alfa received the highest-level recommendation for first- and second-level prevention in the "Guidelines of CSCO for the Diagnosis, Prevention, and Management of Antitumor Therapy-Induced Neutropenia (2025)".

The world's first generic degarelix acetate (Qinglishu®), developed by Chia Tai Tianqing, was approved for marketing and was granted a 12-month market exclusivity period in China, marketing approval in Europe, and tentative approval in the United States, for patients with prostate cancer who require androgen deprivation therapy.

Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharm, attended the 25th China International Fair for Investment & Trade (CIFIT) and called for at the roundtable forum "Dialogue between Well-known Private Enterprises and Fortune 500 Companies" that Chinese and foreign cooperation should "appreciate each other's beauty, and share the beauty together" to allow more innovative achievements to benefit patients worldwide.

The grand ceremony commemorating the 80th anniversary of the victory in the Chinese People's War of Resistance Against Japanese Aggression and the World Anti-Fascist War was held in Tiananmen Square, Beijing. Mr. Dhanin Chearavanont, President of the China Federation of Overseas Chinese Entrepreneurs and Senior Chairman of Charoen Pokphand Group, watched the ceremony from the Tian'anmen Rostrum. Ms. Cheng Cheung Ling, President of CP Pharmaceutical Group, Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharm, and Mr. Eric Tse, Chief Executive Officer, were also in the VIP viewing area, witnessing the nation's strength and glory.

Sino Biopharm and Boehringer Ingelheim announced that Zongertinib Tablets (Hernexeos®), co-marketed in mainland China, has been approved for marketing by the NMPA. It is the world's first oral targeted drug for advanced non-small cell lung cancer with HER2 mutations.

Sino Biopharm released its 2025 interim report, continuing its outstanding performance of high growth in revenue and net profit: In the first half of 2025, the company's revenue reached RMB 17.57 billion, with a year-on-year increase of 10.7%; the net profit attributable to the parent company from continuing operations was RMB 3.39 billion, with a substantial increase of 140.2%; and the adjusted net profit attributable to the parent company was RMB 3.09 billion, with a year-on-year increase of 101.1%.

Ms. Cheng Cheung Ling, President of CP Pharmaceutical Group, and Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, led a delegation to visit The Hong Kong Polytechnic University to exchange ideas with President Professor Teng Jin-Guang and a team of research experts, and to map out a new vision for future cooperation and development.

Ms. Cheng Cheung Ling, President of the Hong Kong China Friendship Association and President of CP Pharmaceutical Group, attended the Policy Address Consultation Session at the Hong Kong SAR Government headquarters and submitted a proposal. Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, attended the consultation session and spoke, expressing his hope to accelerate the "Good Drugs for Use in Hong Kong" initiative for innovative drugs from the mainland.

Adalimumab (Taibowei®), developed by Chia Tai Tianqing, received marketing approval from the Algerian Medicines Agency. This will bring a high-quality and affordable new treatment option to patients with autoimmune diseases in countries participating in the "Belt and Road" initiative.

Sino Biopharm made a major announcement that it had completed the acquisition of 100% equity in LaNova Medicines at a valuation of approximately US$1 billion, drawing widespread attention from the global industry. The event was hailed as a landmark acquisition of a top biotech company by a leading domestic pharmaceutical enterprise in China.

The "2024 Top 100 Pharmaceutical Companies in China" list was released. Chia Tai Tianqing ranked 9th, entering the national top 10 for the first time. Beijing Tide Pharmaceutical ranked 65th, making the list for 13 consecutive years. Benmelstobart and Efbemalenograstim alfa were selected for the "Showcase of Innovative Achievements in the Biopharmaceutical Field".

Recombinant Human Coagulation Factor VIIa N01 (Anqixin®), developed by Chia Tai Tianqing, was approved for marketing for the treatment of haemorrhage in patients with congenital haemophilia. It is the first domestically produced recombinant human coagulation factor VIIa biologic.

Sino Biopharm was selected for the Forbes China "2024-2025 Sustainable Development Industrial Enterprises" list, becoming the only pharmaceutical company on the main list. This is the third consecutive year the Group has received a major award from the Forbes ESG series.

The 16th Annual Meeting of the New Champions 2025 of the World Economic Forum (Summer Davos Forum) was held in Tianjin. Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, attended the opening ceremony of the forum and a symposium with business representatives, and delivered a keynote speech titled "Embracing AI Opportunities, Breaking Down Integration Barriers, and Accelerating Innovative Drug R&D in the Asia-Pacific Region".

Chia Tai Tianqing has been ranked among the top 3 on the "TOP 100 Chinese Pharmaceutical Companies by Comprehensive R&D Strength" for ten consecutive years, ranking second on the "TOP 100 Chinese Chemical Drug Companies by R&D Strength" list and sixth on the "TOP 50 Chinese Biopharmaceutical Companies by R&D Strength" list.

The U.S. magazine Pharm Exec released its "2025 Top 50 Global Pharma Companies" list. Sino Biopharm was listed for the seventh consecutive year, ranking 39th globally and 2nd in China.

CTTQ's Lianyungang Runzhong Pharmaceutical "A Composition of Diammonium Glycyrrhizinate" (ZL200610040759.8) received the 25th "China Patent Excellence Award" from the China National Intellectual Property Administration.

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. Sino Biopharm showcased over 40 innovative research achievements on the global stage, setting a new record for a Chinese pharmaceutical company with 12 oral presentations. Anlotinib accounted for 9 of these, the most for any domestically developed innovative drug.

Meloxicam Injection (II) (Putanning®) received marketing approval from NMPA of China and the U.S. FDA for the management of postoperative pain in adults, becoming China's first once-daily, 24-hour long-acting non-steroidal anti-inflammatory drug (NSAID) injection.

The 5th CICC Pharmaceutical and Healthcare Industry Summit was opened in Shanghai. Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharm, attended and delivered a speech titled "Layout Strategies for Platform-Based Big Pharma Amid the Innovation Wave in the Pharmaceutical Industry".

Sino Biopharm was included for the first time in S&P Global's Sustainability Yearbook (Global Edition) and was rated in the top 5% of the pharmaceutical industry. In December, the Group's S&P CSA ESG score improved again, ranking in the top 6% of global pharmaceutical companies for the second consecutive year and among the top 3% of Chinese companies.

Sino Biopharm and JD Health signed a deepened strategic cooperation agreement in Beijing. The two parties will engage in the in-depth cooperation in areas such as full-category supply chain, omnichannel retail, and innovative marketing models.

Sino Biopharm Leading (Shanghai) Private Investment Fund was unveiled and established in Pudong New Area with a target total size of RMB 1 billion. This is a major initiative by Sino Biopharm to invest in, empower, and cultivate innovation, following its commitment to comprehensive innovative development.

The 2025 China Medical Development Conference was held in Beijing. Ms. Cheng Cheung Ling, President of CP Pharmaceutical Group, and Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, attended the conference. Mr. Eric Tse spoke at the clinical medicine sub-forum on the topic of "Leveraging AI to Support Full-Cycle Patient Health Management and Help Build a China-Led Asia-Pacific Multicenter Clinical Alliance".

Internationally renowned consulting firm Citeline released the "2025 Pharma R&D Annual Review", in which Sino Biopharm's R&D pipeline ranked 2nd in China and 15th globally in terms of size.

The China Development Forum 2025 Annual Meeting was held in Beijing. Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, attended and actively offered suggestions in sessions such as the closed-door meeting on "Implementing the Health-First Development Strategy and Promoting Coordinated Development and Governance of Medical Care, Medical Insurance, and Medicine".

Chia Tai Tianqing and the Greater China Cancer Foundation signed a Named Patient Program (NPP) cooperation agreement of Caring Pharma Partner in Hong Kong. Under the NPP, the two parties will provide innovative treatment options for patients in Hong Kong with urgent medical needs.

Sino Biopharm released its 2024 annual report. The company achieved double-digit growth in both revenue and net profit: Full-year revenue for 2024 reached RMB 28.87 billion, a year-on-year increase of 10.2%, setting a new record high; adjusted net profit attributable to the parent company reached RMB 3.46 billion, a year-on-year increase of 33.5%.

The "Forbes China 2025 Top 100 Outstanding Businesswomen" list was released. Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharm, was listed for the seventh time.

Penpulimab Injection (Annike®) was approved for its 4th indication, for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in combination with chemotherapy. On April 24, it was approved for marketing by the U.S. FDA, becoming the first innovative biologic drug from China to be independently led through the entire process and successfully launched in the United States.

Eribulin Mesilate Injection (Ailelin®), developed by Chia Tai Tianqing, received marketing approval from the U.S. Food and Drug Administration (FDA).

Mr. Eric Tse, Chief Executive Officer of Sino Biopharm and Chairman of Chia Tai Tianqing, was elected as Vice Chairman of the Shanghai Federation of Industry and Commerce Biopharmaceutical Chamber of Commerce.

Zhou Hongbo, Secretary of the Nanjing Municipal Party Committee, met with a delegation led by Eric Tse, Chief Executive Officer of Sino Biopharm and Chairman of Chia Tai Tianqing. Nanjing will strongly support companies like Chia Tai Tianqing in increasing capital and expanding production, innovative R&D, and market expansion, to build them into ten-billion-level chain-leading enterprises.

The first domestic generic Tulobuterol Patches (Deruituo®) and Loxoprofen Sodium Cataplasms (Deshuping®), developed by Beijing Tide Pharmaceutical, were simultaneously approved for marketing.

The Annual Meeting 2025 of World Economic Forum (Winter Davos Forum) was held in Switzerland. Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, attended and delivered a speech titled "Promoting Global Health Development Through Technological Progress and Multilateral Cooperation".

Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharm, was selected for "Bloomberg 50 of the Year 2024", and an interview titled "Theresa Tse, Chairwoman of the Board of Sino Biopharm: Only Innovation Can Secure a Foothold in the Global Pharmaceutical Competition" was published.

Sino Biopharm announced that Chia Tai Tianqing has signed an exclusive marketing agreement with Shionogi to introduce Naldemedine, a treatment for opioid-induced constipation.

"The Lighting up the World Project" public welfare program released its 2024 annual report. Throughout the year, 16 public welfare anti-cancer care events were held, and more than RMB 7.4 million in charitable funds were raised.

The awards ceremony for the 9th The Magnificent Light National Medical Staff Photography Exhibition was held in Hangzhou.

The Ministry of Industry and Information Technology announced the "2024 Green Manufacturing List", and Nanjing Chia Tai Tianqing was selected as a "National Green Factory".

Chia Tai Tianqing signed its first cooperation framework agreement with the Faculty of Medicine of The Chinese University of Hong Kong, establishing a strategic partnership.

The Yangtze River Delta Biopharmaceutical Industry Development Conference was held in Hangzhou. Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, delivered a speech on behalf of leading biomedical enterprises.

The new National Reimbursement Drug List was announced. Two of Chia Tai Tianqing's exclusive new drugs, Unecritinib and Envonalkib, were included for the first time, both of which were launched within the year.

Sino Biopharm was honored with the "ESG Leading Enterprise 2024" award by Bloomberg Businessweek.

A new indication for Benmelstobart combined with Anlotinib for endometrial cancer was approved for marketing. This is the second indication approved for this combination therapy in less than 7 months.

Sino Biopharm announced that it had signed an equity investment and strategic cooperation agreement with LaNova Medicines. Sino Biopharm will invest its own funds for a stake in LaNova Medicines and has reached a strategic cooperation for LM-108 and multiple potential future innovative bispecific antibody or Antibody-Drug Conjugate (ADC) drugs in mainland China.

Chia Tai Tianqing's fourth-generation EGFR inhibitor TQB3002 receiving approval for Investigational New Drug (IND) application from the U.S. FDA, with a Phase I clinical trial set to commence soon.

At the China Healthcare Summit of Entrepreneurs, Scientists and Investors, Sino Biopharm was ranked 3rd in the "Top 100 Innovative Enterprises", listed in the "Top 20 Listed Companies for ESG Competitiveness" (Large Cap), and the "Top 10 Low-Carbon Pioneer Listed Companies for Climate Change Response". Anlotinib was selected for the "Top 20 Blockbuster New Drugs in China".

The Class 1 innovative drug, KRAS G12C inhibitor Garsorasib Tablets (Anfangning®), co-developed by Sino Biopharm, was approved for marketing, tackling a previously "undruggable" target.

Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, visited Fujian and Guangdong as part of a delegation from the Hong Kong CPPCC (Provincial) Members Association. He attended in his capacity as Deputy Secretary-General of the association and a member of the Beijing Municipal Committee of the CPPCC.

Sino Biopharm announced that it would acquire up to 55% of the shares of HOB Biotech Group Corp., Ltd. ("HOB"), a company listed on the STAR Market (688656.SH), through a combination of agreement transfer and tender offer. HOB will become Sino Biopharm's first listed subsidiary in the A-share market.

CP Pharmaceutical Group and Sino Biopharm's Beijing headquarters celebrated their relocation, marking a new chapter in the company's development.

The Asia Conference on Lung Cancer was held in Hong Kong. Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, was invited to attend and proposed making Hong Kong a "super value-adder" for China's pharmaceutical innovation.

Sino Biopharm announced that Chia Tai Tianqing had signed an exclusive license and cooperation agreement with Wuhan YZY Biopharma Co., Ltd. to in-license M701, a Class 1 innovative bispecific antibody developed by YZY Biopharma.

CP Pharmaceutical Group signed a comprehensive strategic cooperation and investment promotion agreement with Quanzhou and Jinjiang.

Beijing Tide Pharmaceutical's Rivastigmine Transdermal Patch (Suleda®) was approved for marketing for the treatment of symptoms of mild to moderate Alzheimer's disease.

The Minister of Ministry of Health of Kazakhstan and her delegation met with Mr. Tse Ping, Senior Vice Chairman of CP Group and Founding Chairman of Sino Biopharm, to discuss cooperation opportunities.

Two schools in Anhui Province welcomed brand-new campus environments. Chia Tai Tianqing contributed over RMB 500,000 to help the schools renovate teaching buildings and upgrade playgrounds, continuing its support for educational public welfare.

The "Top 100 Pharmaceutical Companies in China" list was authoritatively released. Chia Tai Tianqing was ranked 12th and Beijing Tide Pharmaceutical was ranked 66th. Both companies were named "2024 Best Industrial Enterprises for Pharmaceutical R&D Pipelines in China".

The "Technology+New Quality Productive Forces Summit Forum" was held in Hong Kong. John Ka Chiu Lee and Zheng Yanxiong attended and delivered speeches. Ms. Cheng Cheung Ling, President of the Hong Kong China Friendship Association and President of CP Pharmaceutical Group, delivered the opening remarks, expressing her hope that everyone would invest and establish businesses in Hong Kong. Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, proposed focusing on "innovation", "high quality", and the "new quality chain" to develop new quality productive forces.

The Morgan Stanley Capital International (MSCI) 2024 Environmental, Social, and Governance (ESG) ratings were released. Sino Biopharm received an A rating for the second consecutive year. In December, the S&P Corporate Sustainability Assessment (CSA) ESG scores were announced, with the Group's global ranking breaking into the top 4%.

The "First China Health Management Conference" was held in Beijing. Ms. Cheng Cheung Ling, President of CP Pharmaceutical Group and Vice Chairwoman of the Board of Sino Biopharm, was invited to attend and recommended building a more competitive innovation ecosystem.

Sino Biopharm held its semi-annual results press conference. In the first half of the year, Sino Biopharm achieved double-digit growth in both revenue and profit, with semi-annual revenue reaching a new high of RMB 15.87 billion.

Zongertinib was granted Breakthrough Therapy Designation by the CDE. Zongertinib is one of the products under the strategic cooperation between Sino Biopharm and Boehringer Ingelheim in mainland China.

Chia Tai Tianqing and Huawei announced a strategic cooperation to explore collaboration in areas such as digital transformation, AI-assisted drug development, data governance, and intelligent manufacturing.

A delegation led by Liu Cigui, a standing committee member of the National Committee of the CPPCC and Director of the Committee for Liaison with Hong Kong, Macao, Taiwan and Overseas Chinese, visited Beijing Tide Pharmaceutical for an investigation and survey. Ms. Cheng Cheung Ling, President of CP Pharmaceutical Group, and Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharm, accompanied the investigation.

A research paper on the study of Benmelstobart and Anlotinib combined with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer, conducted by Chia Tai Tianqing, was published online in "Nature Medicine" (IF=58.7). The study set a new record for median Overall Survival (mOS) in a registrational study.

Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, was invited to the Forbes Under 30 Summit China. He encouraged young entrepreneurs to cultivate themselves and grow steadfastly with the principles of "cognitive iteration, an empty-cup mindset, and embracing diversity".

At the China Pharmaceutical R&D Innovation Summit, Chia Tai Tianqing was ranked among the top 3 on the "Top 100 Chinese Pharmaceutical Companies by Comprehensive R&D Strength" for the 9th consecutive year. It ranked 2nd on the "Top 100 Chinese Chemical Drug Companies by R&D Strength" list and 5th on the "Top 50 Chinese Biopharmaceutical Companies by R&D Strength" list.

Mr. Chen Jining, Secretary of the CPC Shanghai Municipal Committee, met with Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, and expressed full-chain support for biomedical technology innovation and industrial development. Mr. Eric Tse provided an update on the cooperation plan with Boehringer Ingelheim (BI) and the progress of the global R&D center project.

Xu Kunlin, Governor of Jiangsu Province, visited Chia Tai Tianqing Pharmaceutical Group Co., Ltd. for an investigation. Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, presented the company's development of new quality productive forces in the pharmaceutical sector.

Sino Biopharm was ranked second on the "Top 100 Chinese Chemical Pharmaceutical Companies" list.

Chia Tai Tianqing's Liraglutide Injection (Beilelin®) was approved for marketing, marking its official entry into the field of major recombinant hypoglycemic peptide drugs, including Glucagon-like peptide-1 (GLP-1) and insulin analogs.

PharmExec released its 2024 list of the Top 50 Global Pharmaceutical Companies, with Sino Biopharm ranking 38th.

The Jiangsu Industrial Technology Research Institute (JITRI) established the "JITRI-Chia Tai Qingjiang Joint Innovation Center" at Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd., which will foster close cooperation in areas such as technological needs, strategic research, collaborative R&D mechanisms, and key talent culture.

Chia Tai Tianqing's Class 1 innovative drug, the new-generation ALK inhibitor Envonalkib Citrate Capsules (Anluoqing®), was approved for marketing. Two new indications for the KRAS G12C inhibitor Garsorasib were included in the Breakthrough Therapy Designation program by CDE.

Chia Tai Tianqing signed Strategic Cooperation Framework Agreements with Sinopharm Group and China Resources Pharmaceutical Commercial Group Co., Ltd., respectively, to cooperate in areas such as drug R&D, production, logistics and distribution, SPS+ specialty pharmacies, and import/export business.

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting commenced. Sino Biopharm announced 52 latest research findings on innovative tumor drugs such as Anlotinib and Efbemalenograstim alfa.

The Asia Summit on Global Health opened. Ms.Theresa Tse, Chairwoman of the Board, and Ms. Cheng Cheung Ling, Vice Chairwoman of the Board of Sino Biopharm, were invited to attend. Ms. Theresa Tse shared experiences in R&D innovation and international cooperation, and discussed global opportunities for the industry.

Sino Biopharm announced that its Board of Directors had resolved to approve the implementation of a share incentive plan by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. to motivate core talent who play a crucial role in the future operations and development of Chia Tai Tianqing.

CP Pharmaceutical Group and Beijing Tide Pharmaceutical donated RMB 1 million to the Fujian Youth Development Foundation.

Chia Tai Tianqing's Class 1 innovative drug, Benmelstobart Injection (Andewei®), was approved for marketing in combination with Anlotinib, carboplatin, and etoposide for the first-line treatment of patients with extensive-stage small cell lung cancer. This marks the sixth indication for Anlotinib. On the same day, a new indication for Penpulimab (Annike®) for the treatment of nasopharyngeal cancer was approved.

Chia Tai Tianqing's Class 1 innovative drug, Unecritinib Fumarate Capsules (Anboni®), was approved for marketing, becoming the first domestically developed targeted drug approved for adult patients with ROS1-positive non-small cell lung cancer.

The China Medical Development Conference was held. Mr. Eric Tse, Chief Executive Officer of Sino Biopharm, was invited to attend the conference and stated that enhancing new quality productive forces in the pharmaceutical industry requires a focus on innovation from the source.

The 76th Annual Meeting of the American Academy of Neurology (AAN) commenced. FNND1002, a First-in-Class innovative drug independently developed by Chia Tai Fenghai, was presented at the conference in the form of an oral selected poster.

Sino Biopharm and Boehringer Ingelheim entered into a strategic cooperation agreement. The two parties will leverage their respective strengths and resources to promote faster and better access to global innovative drugs for patients in China.

Nanjing Chia Tai Tianqing's antiviral product, Letermovir tablets, was approved, becoming the first generic of its kind in China. The injectable form of Letermovir was approved for marketing in October, once again securing the first-to-market generic status in China.

Mr. Liu Jianchao, Minister of the International Department of the CPC Central Committee, met with Mr. Dhanin Chearavanont, Senior Chairman of Charoen Pokphand Group (CP Group) of Thailand, in Bangkok.

Efbemalenograstim alfa Injection (Ryzneuta®) was approved for marketing in the European Union, becoming the first innovative G-CSF from China to be approved for marketing in China, the United States, and the European Union.

Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharm, was listed in the "Forbes China Top 100 Businesswomen".

Sino Biopharm signed a strategic cooperation framework agreement with Qingdao Conson Development (Group) Co., Ltd. and Marine Biomedical Research Institute of Qingdao to carry out in-depth strategic cooperation in fields such as finance and the life and health industry.

The Chinese Society of Clinical Oncology (CSCO) released its first "Chinese Expert Consensus on Second-Line Treatment of Non-Small Cell Lung Cancer with Negative Driver Gene". Anlotinib was the only anti-angiogenic drug recommended, filling the gap in second-line targeted therapy for driver-gene-negative cases.

Ms.Theresa Tse, Chairwoman of the Board of Sino Biopharm, was invited to attend the Guangzhou High-Quality Development Conference.

Sino Biopharm's Southern Headquarters held its opening ceremony on Guangzhou International Bio Island and officially commenced operations.

Lianyungang Runzhong Pharmaceutical passed the on-site investigation by the U.S. FDA with "zero defects". This was the third consecutive time Runzhong Pharmaceutical passed with "zero defects".

Sino Biopharm signed a strategic partnership agreement with Shanghai Pharmaceuticals Holding Co., Ltd., establishing a comprehensive strategic cooperation.